🧾 What This Document Is

This is a definitive proxy statement (DEF 14A) for CONMED Corporation's 2026 Annual Meeting. It's like a detailed agenda and report card sent to shareholders before the annual meeting. It explains what will be voted on, provides company performance updates, discloses executive pay, and shares governance details. Think of it as the "shareholder briefing packet."

🏢 What The Company Does

👉 In simple terms, CONMED makes medical devices for minimally invasive surgery, orthopedic soft tissue repair, and smoke evacuation systems. They sell products like surgical tools and implants to hospitals and surgeons globally. It's a healthcare technology company focused on helping doctors perform less invasive procedures.

📅 Key Meeting Details

Date: Monday, May 18, 2026, at 11:30 a.m. EDT.
Format: Virtual only via live webcast at www.virtualshareholdermeeting.com/CNMD2026.
Record Date: March 24, 2026 (you must have owned shares by this date to vote).
Materials Available: The proxy statement and annual report are online at www.proxydocs.com/CNMD.

🗳️ The 3 Proposals You're Voting On

The Board recommends voting FOR all three items.

Election of 7 Directors: Vote to elect the listed nominees for a one-year term. Key additions in 2025 were Mark Kaye (CFO of Elevance Health) and Kim Kelderman (CEO of Bio-Techne).
"Say on Pay" (Advisory Vote): A non-binding vote to approve the compensation of the top executives (Named Executive Officers or NEOs).
Ratify Auditors: Approve PricewaterhouseCoopers LLP (PwC) as the independent accounting firm for 2026.

👥 Board & Management Changes

A year of significant transition and refreshment:

New CEO: Pat Beyer became President and CEO in January 2025 after 11 years at CONMED.
CFO Transition: Todd Garner (CFO of 8 years) is transitioning out. Andrew Moller (Controller) is the interim CFO while a search is conducted.
New Board Chair: LaVerne Council was appointed Board Chair in May 2025.
Board Refreshment: Added two new independent directors (Mark Kaye & Kim Kelderman). Martha Goldberg Aronson (former Chair) and Brian Concannon (Compensation Committee Chair) are departing.
Committee Shuffles: New Chairs for Audit (Mark Kaye) and Compensation (Barbara Schwarzentraub) committees are set for 2026.

💰 2025 Financial Snapshot

Highlighted in the letter to shareholders:

Revenue: $1.375 billion (up 5.2% as reported, 5.1% in constant currency*).
Growth Drivers: Orthopedics sales +5.5% (constant currency), General Surgery +4.7%, with strong momentum in AirSeal® and Buffalo Filter®.
Capital Allocation Shift: Suspended the quarterly cash dividend (Oct 31, 2025) and authorized a $150 million share repurchase program.
Strategic Focus: Exited the gastroenterology product lines to concentrate on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair.

💼 Executive Compensation ("Say on Pay")

This is a core part of the proxy. The philosophy is pay-for-performance, aligning executive interests with shareholders.

2025 NEOs (Named Executive Officers): Patrick Beyer (CEO), Todd Garner (CFO), Hollie Foust (General Counsel), Brent Lalomia (EVP, Regulatory/Quality), Peter Shagory (EVP, Strategy).
Pay Mix: Heavy emphasis on "at-risk" performance-based pay.
- CEO: 50% stock options, 50% Performance Stock Units (PSUs) based on 3-year relative Total Shareholder Return (rTSR).
- Other NEOs: 75% stock options, 25% PSUs.
Annual Bonus: Tied to Net Sales, Adjusted EPS, and Operating Cash Flow goals.
Strong 2025 "Say on Pay" Vote: ~97% approval from shareholders at the last meeting, indicating support for the program.
Ownership Guidelines: Increased in Dec 2025. CEO must hold stock worth 5x base salary; other execs 1.5x.

🏛️ Governance Highlights

The company emphasizes its strong governance framework:

Highly Independent Board: All directors except the CEO are independent. Has an independent Chair.
Annual Elections & Majority Voting: Directors are elected annually. Requires a majority of votes cast for in an uncontested election.
Board Term Limits: A 12-year limit to ensure regular refreshment.
Robust Committee Structure: Four committees: Audit, Compensation, Corporate Governance & Nominating, and Strategy.
Risk Oversight: Board actively oversees major risks (strategy, cybersecurity, regulatory, etc.) through its committees.
Key Policies: Prohibitions on hedging and pledging company stock. A robust clawback policy. 100% attendance at board meetings in 2025.

🔮 What's Next & Strategic Direction

The tone is one of focused execution and transition:

Complete CFO Search: Critical task following Todd Garner's departure.
Execute Strategic Priorities: Drive growth in the three core focused areas (MIS, smoke evacuation, orthopedics).
Realize Efficiencies: Benefit from manufacturing and operating efficiency projects already underway.
Utilize Share Repurchase: Opportunistically use the $150 million buyback authorization.
Maintain Governance: Continue Board refreshment and strong governance practices.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

Focused strategic portfolio after exiting gastroenterology.
Strong revenue growth in core platforms.
Proactive capital allocation (dividend suspension for buybacks).
High level of shareholder support for compensation (97% approval).
Strong and improving governance structure with active board refreshment.

⚠️ Risks & Challenges:

Key Person Risk: Transitioning the CFO role is a significant operational and financial leadership change.
Execution Risk: Success depends on executing the new focused strategy and realizing projected efficiencies.
Market Competition: Operates in competitive medical device markets.
Macroeconomic Factors: Mention of tariff strategies and foreign currency impacts indicate exposure to global economic conditions.

🧠 The Analogy

Think of CONMED as a specialized surgical toolkit that just underwent a major upgrade. The company streamlined its product line (exiting gastroenterology), handed the master surgeon's role to a new leader (CEO Beyer), brought in fresh expert advisors (new Board members), and decided to invest its savings directly back into upgrading the best tools in the kit (share buybacks instead of dividends). Now, with the new toolkit and team, it needs to prove it can perform even more precise and successful operations (drive growth and shareholder value) in its chosen specialties.

🧩 Final Takeaway

This proxy reflects a company in active transition, focusing its strategy, refreshing its leadership (both Board and C-suite), and aligning its capital and governance for the future. Shareholders are being asked to endorse this new direction, approve the leadership's pay (which is heavily tied to performance), and ratify the company's auditors. The key votes are on people (the Board), pay (the NEOs), and process (the auditors), all set against the backdrop of a strategic pivot and financial recalibration.

CONMED Corp — DEF 14A Filing